Is Par Drugs and Chemicals the Best Stock in Its Sector? A Look at the Numbers
- October 5, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Par Drugs and Chemicals CMP Rs 125 (05 Oct 2026). Market cap Rs 153 Cr. ROE 11.71%. P/E 10.52x versus Industry P/E 50.45x.
Quick Answer
Par Drugs and Chemicals is one of the names investors compare when screening the Healthcare sector, built on a 11.71% return on equity and a P/E of 10.52x against an Industry P/E of 50.45x. Whether Par Drugs and Chemicals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Par Drugs and Chemicals the best stock in its sector? The stock trades on the NSE at Rs 125 as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00. Par Drugs and Chemicals Ltd, based in Vadodara, makes magnesium-based active pharmaceutical ingredients and antacid raw materials at its Bhavnagar plant.
Par Drugs and Chemicals sits in the Healthcare sector, and its 11.71% ROE and 10.52x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Par Drugs and Chemicals
Par Drugs and Chemicals Ltd, based in Vadodara, makes magnesium-based active pharmaceutical ingredients and antacid raw materials at its Bhavnagar plant. The stock rose about 1 percent during this session and is trading in the lower half of its 52-week range, about 31 percent below its high. At a market capitalisation of Rs 153 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Par Drugs and Chemicals the Best Stock in Its Sector?
Par Drugs and Chemicals makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 11.71% ROE with a 10.52x P/E against the sector’s 50.45x Industry P/E. Par Drugs and Chemicals’ 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading.
| Metric | Par Drugs and Chemicals |
|---|---|
| CMP (NSE) | Rs 125.00 |
| 52-Week High / Low | Rs 180.00 / Rs 78.05 |
| Market Cap | Rs 153 Cr |
| P/E (TTM) vs Industry P/E | 10.52x vs 50.45x |
| P/B | 1.36 |
| ROE | 11.71% |
| EPS (TTM) | Rs 11.78 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.00 |
Compare Par Drugs and Chemicals Against Other Healthcare Sector Stocks
How Par Drugs and Chemicals Compares Against Its Healthcare Sector Peers
The table below sets Par Drugs and Chemicals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Par Drugs and Chemicals | 153 | 10.52 | 11.71% | 0.00 |
| Lincoln Pharmaceuticals | 1,172 | 12.15 | 11.60% | 0.01 |
| Medico Remedies | 179 | 13.00 | 17.38% | 0.25 |
| Peer average (2 companies) | – | 12.57 | 14.49% | 0.13 |
Against this peer set, Par Drugs and Chemicals’s 11.71% ROE is below the 14.49% peer average, and its P/E of 10.52x runs below the peer average of 12.57x. Par Drugs and Chemicals’ 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading.
What Makes Par Drugs and Chemicals Worth Watching in Healthcare
- Well below Industry P/E: A 10.52x P/E against a 50.45x Industry P/E is a wide discount for a business with an 11.71% ROE.
- Debt free balance sheet: A debt to equity ratio of 0.00 gives Par Drugs and Chemicals complete flexibility to fund operations internally.
- Antacid ingredients niche: Being a large producer of magnesium hydroxide and sucralfate gives Par Drugs and Chemicals a specialised position in antacid raw materials.
Par Drugs and Chemicals Valuation: Is It Justified?
Par Drugs and Chemicals’ 10.52x P/E is far below the 50.45x Industry P/E despite an 11.71% ROE, making it look inexpensive relative to its own quality, though it is a small-cap with thin trading. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oricon Enterprises the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Par Drugs and Chemicals and other Healthcare sector stocks.
How to Track Par Drugs and Chemicals Before You Invest
Before deciding whether Par Drugs and Chemicals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Par Drugs and Chemicals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Par Drugs and Chemicals earns a place in the best stock in its sector conversation on the strength of a 11.71% ROE and a P/E of 10.52x against a 50.45x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Par Drugs and Chemicals the best stock in its sector?
Ans. Par Drugs and Chemicals has a 11.71% ROE and trades at 10.52x P/E against a 50.45x Industry P/E, and compares below the peer average ROE of 14.49% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Par Drugs and Chemicals?
Ans. Par Drugs and Chemicals was trading at Rs 125.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00.
What sector does Par Drugs and Chemicals belong to?
Ans. Par Drugs and Chemicals is classified under the Healthcare sector on Univest.
How does Par Drugs and Chemicals compare to its sector peers on P/E?
Ans. Par Drugs and Chemicals’s P/E of 10.52x is below the 12.57x average of the 2 named peers compared in this article.
What is Par Drugs and Chemicals’s return on equity?
Ans. Par Drugs and Chemicals reported a return on equity of 11.71%, which is below the 14.49% average of its named peers in this comparison.
Should I invest in Par Drugs and Chemicals based on its sector position?
Ans. Par Drugs and Chemicals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Par Drugs and Chemicals the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals has a 11.71% ROE and trades at 10.52x P/E against a 50.45x Industry P/E, and compares below the peer average ROE of 14.49% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Par Drugs and Chemicals?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals was trading at Rs 125.00 on the NSE as of 05 October 2026, within its 52-week range of Rs 78.05 to Rs 180.00.”}}, {“@type”: “Question”, “name”: “What sector does Par Drugs and Chemicals belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Par Drugs and Chemicals compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals’s P/E of 10.52x is below the 12.57x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Par Drugs and Chemicals’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals reported a return on equity of 11.71%, which is below the 14.49% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Par Drugs and Chemicals based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Par Drugs and Chemicals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}
